However, endometrial cancer remains a small use, and Jemperli has other ways to make a bigger splash.

Curiously, however, higher dosing does not seem to be the answer to the company’s relapse problem.

First data with the biotech’s new EGFR project prompts a 236% share price bump.

The company puts its faith in a new lymphodepletion regimen to overcome mediocre early results with its lead Car-NK therapy.

Having impressed two years ago, Dizal returns with even more comprehensive targeted therapy data.

Toxicity casts a shadow over vorasidenib’s prospects as possibly the first targeted therapy for low-grade glioma.